First Genetically Engineered Pig Lung Transplanted into a Human Survives 9 Days
A six-gene-edited pig lung transplanted into a brain-dead male recipient functioned for 216 hours, marking a historic xenotransplantation milestone.
Summary
Chinese surgeons transplanted a lung from a genetically engineered pig into a 39-year-old brain-dead man following a brain hemorrhage, monitoring the organ for nine days. The pig donor had six gene edits designed to reduce immune rejection. The transplanted lung remained viable throughout the 216-hour observation period with no hyperacute rejection or infection detected. Significant swelling resembling primary graft dysfunction appeared at 24 hours, likely from ischemia-reperfusion injury. Antibody-mediated rejection caused damage on days 3 and 6, with partial recovery by day 9. An intensive immunosuppression regimen was required. While challenges around rejection and infection persist, this case establishes that pig-to-human lung xenotransplantation is feasible and sets the stage for further preclinical research.
Detailed Summary
Organ donor shortages kill thousands of patients each year awaiting lung transplants. Xenotransplantation — transplanting organs from animals into humans — has long been pursued as a potential solution, but the lung has remained an especially daunting frontier due to its direct exposure to the immune system and the environment. According to the authors, genetically engineered pig lungs had not previously been transplanted into humans, making this the first reported case of its kind.
Researchers at Guangzhou Medical University transplanted a lung from a six-gene-edited pig into a 39-year-old brain-dead male recipient who had suffered a brain hemorrhage. The genetic modifications were designed to reduce immune attack and improve compatibility with human physiology. The team monitored the xenograft continuously over a 216-hour (nine-day) postoperative period.
The transplanted lung maintained viability and respiratory function throughout monitoring. Critically, no hyperacute rejection — the rapid, catastrophic immune attack most feared in xenotransplantation — was observed. At 24 hours, severe pulmonary edema consistent with primary graft dysfunction appeared, attributed to ischemia-reperfusion injury during transplantation. Antibody-mediated rejection caused measurable organ damage on postoperative days 3 and 6, though partial recovery was documented by day 9.
The immunosuppression protocol was aggressive and multifaceted, including rabbit anti-thymocyte globulin, basiliximab, rituximab, eculizumab, tofacitinib, tacrolimus, mycophenolate mofetil, and tapering steroids — adjusted dynamically based on real-time immune assessments.
The findings demonstrate proof-of-concept feasibility for pig-to-human lung xenotransplantation while honestly cataloguing remaining barriers. Rejection management and infection risk are unsolved problems. The brain-dead recipient model, while ethically appropriate for a first-in-human test, limits conclusions about long-term function or conscious patient outcomes. Substantial preclinical work is needed before any clinical application. Still, this milestone moves the field meaningfully forward.
Key Findings
- Pig lung transplanted into a brain-dead man survived 216 hours with no hyperacute rejection detected.
- Six targeted gene edits in the pig donor appeared sufficient to prevent catastrophic immediate immune rejection.
- Antibody-mediated rejection emerged on days 3 and 6 but partially resolved by day 9 with adjusted immunosuppression.
- Severe edema at 24 hours resembled primary graft dysfunction, likely driven by ischemia-reperfusion injury.
- An eight-drug immunosuppression regimen was required, highlighting the complexity of managing xenograft immune responses.
Methodology
This is a single case report of pig-to-human bilateral lung xenotransplantation performed in a brain-dead 39-year-old male recipient. The pig donor carried six gene edits targeting xenoreactive antigens and human compatibility factors. Monitoring was conducted over 216 hours with serial immune assessments guiding immunosuppression adjustments.
Study Limitations
This is a single case in a brain-dead recipient, severely limiting generalizability and precluding any conclusions about patient outcomes in a living, conscious individual. Full study data are not available as this summary is based on the abstract only. The authors themselves caution that substantial preclinical work remains before clinical translation is appropriate.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: